The Goldman Sachs Group Issues Pessimistic Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price
Relay Therapeutics (NASDAQ:RLAY – Free Report) had its price objective lowered by The Goldman Sachs Group from $20.00 to $18.00 in a research report released on Thursday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. RLAY has been the topic of several other research reports. JMP Securities reissued a “market […]
Relay Therapeutics (NASDAQ:RLAY – Free Report) had its price objective lowered by The Goldman Sachs Group from $20.00 to $18.00 in a research report released on Thursday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. RLAY has been the topic of several other research reports. JMP Securities reissued a “market […]
